Haemonetics Co. (NYSE:HAE) Holdings Lowered by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in Haemonetics Co. (NYSE:HAE) by 6.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,940,224 shares of the medical instruments supplier’s stock after selling 261,341 shares during the quarter. Wellington Management Group LLP owned approximately 7.84% of Haemonetics worth $307,653,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets raised its holdings in shares of Haemonetics by 174.5% during the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 10,774 shares during the period. Boston Trust Walden Corp raised its stake in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after purchasing an additional 106,114 shares during the period. FMR LLC lifted its holdings in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Haemonetics in the fourth quarter worth $319,000. Finally, Pacer Advisors Inc. raised its position in Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier’s stock valued at $789,000 after buying an additional 2,680 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.0 %

NYSE:HAE opened at $62.94 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company’s 50 day moving average is $65.60 and its 200-day moving average is $74.54. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 24.78, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on HAE shares. Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. started coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities lowered their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.